BVAXF Stock - BioVaxys Technology Corp.
Unlock GoAI Insights for BVAXF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-3,122,149 | $-2,402,602 | $-3,802,799 | $-5,979,255 | $-1,009,072 |
| Net Income | $-3,954,781 | $-7,687,317 | $-11,727,444 | $-6,457,939 | $-1,174,311 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.20 | $-0.57 | $-1.20 | $-0.78 | $-0.39 |
BioVaxys Technology Corp., a clinical biotechnology company, develops antiviral and anticancer vaccine platforms. It develops BVX-0320, a monovalent SARS-CoV-2 vaccine; and BVX-0918A, a haptenized tumor cell vaccine for ovarian cancer, as well as CoviDTH, which screens for an immune system response in patients exposed to SARS-CoV-2. The company is also developing Papilocare for human papilloma virus (HPV)-dependent cervical lesions; BVX-0918C for cervical cancer; BVX-0204 HPV viral vaccine; and BVX-0121, a multivalent SARS-CoV-2 vaccine. BioVaxys Technology Corp. has a bioproduction agreement with WuXi Biologics Limited that produces SARS-CoV-2 s-proteins for BVX-0320 and CoviDTH; research collaboration with The Ohio State University, Wexner School of Medicine for BVX-0320; and agreement with Bioanalytical Systems, Inc. to conduct preclinical toxicology studies for its CoviDTH immunodiagnostic. The company is based in Vancouver, Canada.
Visit WebsiteEarnings History & Surprises
BVAXFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2025 | Mar 31, 2025 | — | $-0.00 | — | — |
Q1 2025 | Mar 19, 2025 | — | $-0.01 | — | — |
Q3 2024 | Jul 31, 2024 | — | $-0.00 | — | — |
Q2 2024 | Jun 5, 2024 | — | $0.00 | — | — |
Q2 2024 | Apr 29, 2024 | — | $-0.00 | — | — |
Q4 2023 | Oct 30, 2023 | — | $-0.02 | — | — |
Q3 2023 | Jul 31, 2023 | — | $-0.00 | — | — |
Q2 2023 | Apr 30, 2023 | — | $-0.01 | — | — |
Q1 2023 | Jan 31, 2023 | — | $-0.01 | — | — |
Q4 2022 | Oct 31, 2022 | — | $-0.06 | — | — |
Q3 2022 | Jul 31, 2022 | — | $-0.01 | — | — |
Q2 2022 | Apr 30, 2022 | — | $-0.01 | — | — |
Q1 2022 | Jan 31, 2022 | — | $-0.01 | — | — |
Q4 2021 | Oct 31, 2021 | — | $-0.02 | — | — |
Q3 2021 | Jul 31, 2021 | — | $-0.01 | — | — |
Q2 2021 | Apr 30, 2021 | — | $-0.01 | — | — |
Q1 2021 | Jan 31, 2021 | — | $-0.02 | — | — |
Q4 2020 | Oct 31, 2020 | — | $-0.02 | — | — |
Q3 2020 | Jul 31, 2020 | — | $-0.01 | — | — |
Q2 2020 | Apr 30, 2020 | — | $-0.00 | — | — |
Latest News
Frequently Asked Questions about BVAXF
What is BVAXF's current stock price?
What is the analyst price target for BVAXF?
What sector is BioVaxys Technology Corp. in?
What is BVAXF's market cap?
Does BVAXF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to BVAXF for comparison